Scientists at Institut Pasteur in France have repurposed DPP4 inhibitors, used to treat type 2 diabetes mellitus, to boost the body's immune response to tumors.
While immuno-oncology agents like the PD-1 and PD-L1 inhibitors have revolutionized cancer care by preventing checkpoint blockade, scientists at the Institut Pasteur have discovered another way to manipulate the body's immune response to a tumor—increased infiltration of T-cells to the tumor site.
In their article published in Nature Immunology, the authors show that inhibition of the enzyme dipeptidylpeptidase 4 (DPP4), also a target in diabetes, helps boosts the body's immune response to a tumor by maintaining the activity of CXCL10 and CXCR3 receptors. Preserving the activity of these receptors helps the influx of immune cells at the tumor site, which can help reject tumor growth.
Read more on ScienceDaily: http://bit.ly/1L2zU7v
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More